Clinical implications of amylin and amylin deficiency.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Clinical implications of amylin and amylin deficiency.
- Published In:
- The Diabetes educator, 25(3), 389-97; quiz 398 (1999)
- Authors:
- Kruger, D F, Gatcomb, P M, Owen, S K
- Database ID:
- RPEP-00533
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-00533APA
Kruger, D F; Gatcomb, P M; Owen, S K. (1999). Clinical implications of amylin and amylin deficiency.. The Diabetes educator, 25(3), 389-97; quiz 398.
MLA
Kruger, D F, et al. "Clinical implications of amylin and amylin deficiency.." The Diabetes educator, 1999.
RethinkPeptides
RethinkPeptides Research Database. "Clinical implications of amylin and amylin deficiency." RPEP-00533. Retrieved from https://rethinkpeptides.com/research/kruger-1999-clinical-implications-of-amylin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.